Cystatin C-Cathepsin B Axis Regulates Amyloid Beta Levels and Associated Neuronal Deficits in an Animal Model of Alzheimer's Disease

Neuron

Volumn 60, Issue 2, 2008, Pages 247-257

  Sun, Binggui ^a   Zhou, Yungui ^a   Halabisky, Brian ^a   Lo, Iris ^a   Cho, Seo Hyun ^a   Mueller Steiner, Sarah ^a   Devidze, Nino ^a   Wang, Xin ^a   Grubb, Anders ^b   Gan, Li ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CELLBIO; SYSBIO; SYSNEURO

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; CATHEPSIN B; CYSTATIN C; CYSTEINE PROTEINASE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; BIOLOGICAL MODEL; COGNITIVE DEFECT; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYME ACTIVITY; GENE MUTATION; HIPPOCAMPUS; IN VIVO STUDY; MOUSE; NERVE CELL PLASTICITY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; SYNAPSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; BRAIN; CATHEPSIN B; CYSTATIN C; GENETIC PREDISPOSITION TO DISEASE; MICE; MICE, KNOCKOUT; PEPTIDE FRAGMENTS; POLYMORPHISM, GENETIC; SENILE PLAQUES;

EID: 53849106834     PISSN: 08966273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuron.2008.10.001     Document Type: Article

References (54)

1. Abrahamson M., Barrett A.J., Salvesen G., and Grubb A. Isolation of six cysteine proteinase inhibitors from human urine. Their physicochemical and enzyme kinetic properties and concentrations in biological fluids. J. Biol. Chem. 261 (1986) 11282-11289
2. Benussi L., Ghidoni R., Steinhoff T., Alberici A., Villa A., Mazzoli F., Nicosia F., Barbiero L., Broglio L., Feudatari E., et al. Alzheimer disease-associated cystatin C variant undergoes impaired secretion. Neurobiol. Dis. 13 (2003) 15-21
3. Bertram L., McQueen M.B., Mullin K., Blacker D., and Tanzi R.E. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat. Genet. 39 (2007) 17-23
4. Beyer K., Lao J.I., Gomez M., Riutort N., Latorre P., Mate J.L., and Ariza A. Alzheimer's disease and the cystatin C gene polymorphism: An association study. Neurosci. Lett. 315 (2001) 17-20
5. Bogyo M., Verhelst S., Bellingard-Dubouchaud V., Toba S., and Greenbaum D. Selective targeting of lysosomal cysteine proteases with radiolabeled electrophilic substrate analogs. Chem. Biol. 7 (2000) 27-38
6. Cataldo A.M., and Nixon R.A. Enzymatically active lysosomal proteases are associated with amyloid deposits in Alzheimer brain. Proc. Natl. Acad. Sci. USA 87 (1990) 3861-3865
7. Chen J., Zhou Y., Mueller-Steiner S., Chen L.F., Kwon H., Yi S., Mucke L., and Gan L. SIRT1 protects against microglia-dependent amyloid-β toxicity through inhibiting NF-κB signaling. J. Biol. Chem. 280 (2005) 40364-40374
8. Cheng I.H., Scearce-Levie K., Legleiter J., Palop J.J., Gerstein H., Bien-Ly N., Puolivali J., Lesne S., Ashe K.H., Muchowski P.J., and Mucke L. Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J. Biol. Chem. 282 (2007) 23818-23828
9. Chin J., Palop J.J., Puolivali J., Massaro C., Bien-Ly N., Gerstein H., Scearce-Levie K., Masliah E., and Mucke L. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J. Neurosci. 25 (2005) 9694-9703
10. Cimerman N., Prebanda M.T., Turk B., Popovic T., Dolenc I., and Turk V. Interaction of cystatin C variants with papain and human cathepsins B, H and L. J. Enzyme Inhib. 14 (1999) 167-174
11. Crawford F.C., Freeman M.J., Schinka J.A., Abdullah L.I., Gold M., Hartman R., Krivian K., Morris M.D., Richards D., Duara R., et al. A polymorphism in the cystatin C gene is a novel risk factor for late-onset Alzheimer's disease. Neurology 55 (2000) 763-768
12. Deng A., Irizarry M.C., Nitsch R.M., Growdon J.H., and Rebeck G.W. Elevation of cystatin C in susceptible neurons in Alzheimer's disease. Am. J. Pathol. 159 (2001) 1061-1068
13. Eckman E.A., Reed D.K., and Eckman C.B. Degradation of the Alzheimer's amyloid beta peptide by endothelin-converting enzyme. J. Biol. Chem. 276 (2001) 24540-24548
14. Esposito L., Gan L., Yu G.Q., Essrich C., and Mucke L. Intracellularly generated amyloid-beta peptide counteracts the antiapoptotic function of its precursor protein and primes proapoptotic pathways for activation by other insults in neuroblastoma cells. J. Neurochem. 91 (2004) 1260-1274
15. Finckh U., von der Kammer H., Velden J., Michel T., Andresen B., Deng A., Zhang J., Muller-Thomsen T., Zuchowski K., Menzer G., et al. Genetic association of a cystatin C gene polymorphism with late-onset Alzheimer's disease. Arch. Neurol. 57 (2000) 1579-1583
16. Golde T.E., Eckman C.B., and Younkin S.G. Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. Biochim. Biophys. Acta 1502 (2000) 172-187
17. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297 (2002) 353-356
18. Hook V.Y., Kindy M., and Hook G. Inhibitors of cathepsin B improve memory and reduce Abeta in transgenic Alzheimer's Disease mice expressing the wild-type, but not the Swedish mutant, beta -secretase APP site. J. Biol. Chem. 283 (2008) 7745-7753
19. Hsia A.Y., Masliah E., McConlogue L., Yu G.Q., Tatsuno G., Hu K., Kholodenko D., Malenka R.C., Nicoll R.A., and Mucke L. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl. Acad. Sci. USA 96 (1999) 3228-3233
20. Hsiao K.K., Borchelt D.R., Olson K., Johannsdottir R., Kitt C., Yunis W., Xu S., Eckman C., Younkin S., Price D., et al. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer's amyloid precursor proteins. Neuron 15 (1995) 1203-1218
21. Huh C.G., Hakansson K., Nathanson C.M., Thorgeirsson U.P., Jonsson N., Grubb A., Abrahamson M., and Karlsson S. Decreased metastatic spread in mice homozygous for a null allele of the cystatin C protease inhibitor gene. Mol. Pathol. 52 (1999) 332-340
22. Iwata N., Tsubuki S., Takaki Y., Shirotani K., Lu B., Gerard N.P., Gerard C., Hama E., Lee H.-J., and Saido T.C. Metabolic regulation of brain Aβ by neprilysin. Science 292 (2001) 1550-1552
23. Johnson-Wood K., Lee M., Motter R., Hu K., Gordon G., Barbour R., Khan K., Gordon M., Tan H., Games D., et al. Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 94 (1997) 1550-1555
24. Kaeser S.A., Herzig M.C., Coomaraswamy J., Kilger E., Selenica M.L., Winkler D.T., Staufenbiel M., Levy E., Grubb A., and Jucker M. Cystatin C modulates cerebral beta-amyloidosis. Nat. Genet. 39 (2007) 1437-1439
25. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., and Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300 (2003) 486-489
26. Klein W.L. Aβ toxicity in Alzheimer's disease: Globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem. Int. 41 (2002) 345-352
27. Klyubin I., Walsh D.M., Cullen W.K., Fadeeva J.V., Anwyl R., Selkoe D.J., and Rowan M.J. Soluble Arctic amyloid beta protein inhibits hippocampal long-term potentiation in vivo. Eur. J. Neurosci. 19 (2004) 2839-2846
28. Kobayashi D.T., and Chen K.S. Behavioral phenotypes of amyloid-based genetically modified mouse models of Alzheimer's disease. Genes Brain Behav. 4 (2005) 173-196
29. Leissring M.A., Farris W., Chang A.Y., Walsh D.M., Wu X., Sun X., Frosch M.P., and Selkoe D.J. Enhanced proteolysis of β-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 40 (2003) 1087-1093
30. Lesne S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., Gallagher M., and Ashe K.H. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440 (2006) 352-357
31. Levy E., Sastre M., Kumar A., Gallo G., Piccardo P., Ghetti B., and Tagliavini F. Co-deposition of cystatin C with amyloid-β protein in the brain of Alzheimer disease patients. J. Neuropathol. Neurol. 60 (2001) 94-104
32. Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature 430 (2004) 631-639
33. McConlogue L., Buttini M., Anderson J.P., Brigham E.F., Chen K.S., Freedman S.B., Games D., Johnson-Wood K., Lee M., Zeller M., et al. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice. J. Biol. Chem. 282 (2007) 26326-26334
34. Mi W., Pawlik M., Sastre M., Jung S.S., Radvinsky D.S., Klein A.M., Sommer J., Schmidt S.D., Nixon R.A., Mathews P.M., and Levy E. Cystatin C inhibits amyloid-beta deposition in Alzheimer's disease mouse models. Nat. Genet. 39 (2007) 1440-1442
35. Montaser M., Lalmanach G., and Mach L. CA-074, but not its methyl ester CA-074Me, is a selective inhibitor of cathepsin B within living cells. Biol. Chem. 383 (2002) 1305-1308
36. 1-42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation. J. Neurosci. 20 (2000) 4050-4058
37. Mueller-Steiner S., Zhou Y., Arai H., Roberson E.D., Sun B., Chen J., Wang X., Yu G., Esposito L., Mucke L., and Gan L. Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. Neuron 51 (2006) 703-714
38. Ognibene E., Middei S., Daniele S., Adriani W., Ghirardi O., Caprioli A., and Laviola G. Aspects of spatial memory and behavioral disinhibition in Tg2576 transgenic mice as a model of Alzheimer's disease. Behav. Brain Res. 156 (2005) 225-232
39. Palop J.J., Jones B., Kekonius L., Chin J., Yu G.-Q., Raber J., Masliah E., and Mucke L. Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proc. Natl. Acad. Sci. USA 100 (2003) 9572-9577
40. Palop J.J., Chin J., Roberson E.D., Wang J., Thwin M.T., Bien-Ly N., Yoo J., Ho K.O., Yu G.Q., Kreitzer A., et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 55 (2007) 697-711
41. Qiu W.Q., Walsh D.M., Ye Z., Vekrellis K., Zhang J., Podlisny M.B., Rosner M.R., Safavi A., Hersh L.B., and Selkoe D.J. Insulin-degrading enzyme regulates extracellular levels of amyloid β-protein by degradation. J. Biol. Chem. 273 (1998) 32730-32738
42. Roberson E.D., and Mucke L. 100 years and counting: prospects for defeating Alzheimer's disease. Science 314 (2006) 781-784
43. Roberson E.D., Scearce-Levie K., Palop J.J., Yan F., Cheng I.H., Wu T., Gerstein H., Yu G.Q., and Mucke L. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316 (2007) 750-754
44. Saito T., Iwata N., Tsubuki S., Takaki Y., Takano J., Huang S.M., Suemoto T., Higuchi M., and Saido T.C. Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation. Nat. Med. 11 (2005) 434-439
45. Selkoe D.J. Clearing the brain's amyloid cobwebs. Neuron 32 (2001) 177-180
46. Shankar G.M., Li S., Mehta T.H., Garcia-Munoz A., Shepardson N.E., Smith I., Brett F.M., Farrell M.A., Rowan M.J., Lemere C.A., et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14 (2008) 837-842
47. Tanzi R.E., Moir R.D., and Wagner S.L. Clearance of Alzheimer's Abeta peptide: the many roads to perdition. Neuron 43 (2004) 605-608
48. Townsend M., Shankar G.M., Mehta T., Walsh D.M., and Selkoe D.J. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J. Physiol. 572 (2006) 477-492
49. Tucker H.M., Kihiko M., Caldwell J.N., Wright S., Kawarabayashi T., Price D., Walker D., Scheff S., McGillis J.P., Rydel R.E., and Estus S. The plasmin system is induced by and degrades amyloid-β aggregates. J. Neurosci. 20 (2000) 3937-3946
50. Turk B., Bieth J.G., Bjork I., Dolenc I., Turk D., Cimerman N., Kos J., Colic A., Stoka V., and Turk V. Regulation of the activity of lysosomal cysteine proteinases by pH-induced inactivation and/or endogenous protein inhibitors, cystatins. Biol. Chem. Hoppe Seyler 376 (1995) 225-230
51. Turk B., Turk D., and Salvesen G.S. Regulating cysteine protease activity: essential role of protease inhibitors as guardians and regulators. Curr. Pharm. Des. 8 (2002) 1623-1637
52. Walsh D.M., and Selkoe D.J. A beta oligomers-a decade of discovery. J. Neurochem. 101 (2007) 1172-1184
53. Yin K.J., Cirrito J.R., Yan P., Hu X., Xiao Q., Pan X., Bateman R., Song H., Hsu F.F., Turk J., et al. Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-beta peptide catabolism. J. Neurosci. 26 (2006) 10939-10948
54. 1-40, and its inhibition enhances brain Abeta deposition. J. Neurosci. 27 (2007) 8628-8635